FcResolv® NOG

FcResolv™ NOG Mouse Model
  • Live
  • Mouse
  • Male & Female Available
  • Albino
  • Available for direct purchase by CRO
Model No.NomenclatureGenotype
19164-FNOD.Cg-Fcgr2btm1Ttk Fcer1gtm1Rav Prkdcscid Il2rgtm1Sugko/ko;ko/ko;sp/sp;ko/ko
19164-MNOD.Cg-Fcgr2btm1Ttk Fcer1gtm1Rav Prkdcscid Il2rgtm1Sugko/ko;ko/ko;sp/sp;ko/y
View:
Select One

Overview

Get a more accurate assessment of your antibody-based drug efficacy. Functional knockout of the murine Fc gamma (Fcγ) improves experimental results to get you the right answer faster.

Nomenclature: NOD.Cg-Fcgr2btm1Ttk Fcer1gtm1Rav Prkdcscid Il2rgtm1Sug

 

  • The FcResolv™ NOG is a super immunodeficient NOG mouse that has a further reduction in residual murine immune activity via ablation of mouse Fc gamma receptors (FcγRs) to improve accuracy of results.
  • Murine FcγRs can confound experiments in several ways, leading to false positive or negative results. Removing murine FcγRs provides improved accuracy for efficacy assessment of antibody-based therapies which include an Fc domain.
  • Lacks all murine Fcγ receptors, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.
  • Can be used in a similar fashion to the NOG mouse, including for xenograft and immune system humanization experiments.
  • FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NOG mouse; human cell frequencies may vary somewhat between the two humanized models.

NOG Characteristics

  • Amenable to immune system humanization via engraftment of human hematopoietic stem cells (HSCs).
  • Immunodeficient model lacking mature T, B, and NK cells, with reduced complement activity and dysfunctional macrophages and dendritic cells.
  • Excellent model for a variety of xenograft and human cell engraftment studies.
  • Applications in research involving cancer, infectious disease, immunology, regenerative medicine, humanization, autoimmune disease, immunotherapy, vaccine, GvHD/transplantation, hematopoiesis, inflammation/allergy, and safety assessment.
  • The Il2rg gene is sex-linked.

Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Small image of Infographic Download the Taconic Biosciences' Infographic:
FcResolv™ NOG Mouse Models Are Specifically Designed to Reduce False Positives and Negatives Mediated by Mouse Fc Gamma Receptors in Studies Using Antibody-Based Drugs

See how the FcResolv NOG mouse reduces experimental confounders.

Availability

Available now*

*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age.

Origin

The FcResolv NOG mouse was developed by Takeshi Takahashi of the Central Institute for Experimental Animals (CIEA) in Japan. The Fcer1gtm1Rav mutation was developed in the laboratory of J.V. Ravetch, Sloan-Kettering Institute. The Fcgr2btm1Ttk mutation was developed in the laboratory of T. Takai of Okayama University. These two mutations were backcrossed onto the CIEA NOG mouse®. Taconic received stock in 2021, and the line was derived through embryo transfer. The mice are maintained by breeding females homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid and Il2rgtm1Sug mutant alleles with males that are homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid alleles and hemizygous for the Il2rgtm1Sug mutant allele.

Genetics

Species:Mouse
Strain Type:Congenic
Allele Type:Constitutive Knockout;Spontaneous Mutant
Coat Color:Albino
Genetic Background:NOD

Guides & Publications

Initial Publication: 

  • Katano I, Ito R, Kawai K, Takahashi T. Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse. Front Immunol. 2020 Oct 7;11:532684.
  • Katano I, Hanazawa A, Otsuka I, Yamaguchi T, Mochizuki M, Kawai K, Ito R, Goto M, Kagawa T, Takahashi T. Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. Sci Rep. 2021 Oct 26;11(1):21087.

Applications & Therapeutic Areas

  • Immunology
  • Inflammation
  • Oncology & Immuno-Oncology
  • Cell and Tissue Humanized

Transit, Housing & Welfare

Need more info? Click the live chat button or Contact Us

Packing Practices

Taconic standard practice is to recombine animals of different home cages and/or ages from a single model and sex during packing, except in specific cases where Taconic's animal welfare policy prohibits recombination due to aggression or other concerns.  When an order is fulfilled with animals from more than one week of birth, this standard practice results in animals from a range of birth weeks packed together in a single TTC. When an order is fulfilled with animals from genotyped models, this standard practice results in animals from different home cages packed together in a single TTC.

Customers who wish to keep animals from different weeks of birth separated should place orders with the special instruction "Divide and label by age."  Note that this special request can result in increased costs for additional Taconic Transit Cages, dividers and/or freight charges.

Taconic discourages other types of custom packing requests as they can have a negative impact on animal welfare. Learn more.

Data

FcResolv NOG Permits Accurate Detection of Antibody-based Immunotherapy Efficacy 

Ablating murine FcgR activity enables accurate detection of immunotherapy efficacy in humanized mice engrafted with tumors. Nivolumab (anti-PD1) does not suppress tumor growth in HSC-engrafted NOG mice (bottom row) but displays anti-tumor efficacy in HSC-engrafted FcResolv NOG mice (top row).
Figure 1: Ablating murine FcγR activity enables accurate detection of immunotherapy efficacy in humanized mice engrafted with tumors. Nivolumab (anti-PD1) does not suppress tumor growth in HSC-engrafted NOG mice (bottom row) but displays anti-tumor efficacy in HSC-engrafted FcResolv NOG mice (top row). From Katano et al. 2021.

 

 

HSC-engrafted FcResolv NOG Supports Higher Levels of Human Cells Compared to NOG

FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NOG mouse.
Figure 2: FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NOG mouse. From Katano et al. 2021.

FcResolv® NOG

Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions.

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:

  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Pricing - USD

Opportunist Free (OF) Health Standard

19164 Female

19164-F Genotype ko/ko;ko/ko;sp/sp;ko/ko

Age in WeeksQuantity 1 - 999
3 to 10$369.00

19164 Male

19164-M Genotype ko/ko;ko/ko;sp/sp;ko/y

Age in WeeksQuantity 1 - 999
3 to 10$369.00

Pricing - EUR

Opportunist Free (OF) Health Standard

19164 Female

19164-F Genotype ko/ko;ko/ko;sp/sp;ko/ko

Age in WeeksQuantity 1 - 999
3 to 10€349,00

19164 Male

19164-M Genotype ko/ko;ko/ko;sp/sp;ko/y

Age in WeeksQuantity 1 - 999
3 to 10€349,00

Pricing - USD Nonprofit

Opportunist Free (OF) Health Standard

19164 Female

19164-F Genotype ko/ko;ko/ko;sp/sp;ko/ko

Age in WeeksQuantity 1 - 999
3 to 10$259.00

19164 Male

19164-M Genotype ko/ko;ko/ko;sp/sp;ko/y

Age in WeeksQuantity 1 - 999
3 to 10$259.00

Pricing - EUR Nonprofit

Opportunist Free (OF) Health Standard

19164 Female

19164-F Genotype ko/ko;ko/ko;sp/sp;ko/ko

Age in WeeksQuantity 1 - 999
3 to 10€244,00

19164 Male

19164-M Genotype ko/ko;ko/ko;sp/sp;ko/y

Age in WeeksQuantity 1 - 999
3 to 10€244,00

Select my Health Standard

Need help choosing the right Taconic Biosciences health standard for your research?

Use the Health Standard Selector to enter your exclusion list. The tool will tell you which health standards meet your requirements.

Get custom pricing guide

2024 Pricing Guide Now Available

Get your Taconic Biosciences 2024 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.

Schedule A Scientific Consultation

Speak with a PhD-level Field Application Scientist who can help you select the most appropriate model and maximize your experimental success.

2024 Pricing Guide Now Available

Get your Taconic Biosciences 2024 Pricing Guide today. Personalized, customizable, links to up-to-date health reports, and additional information on Taconic's products and services.